Inclusion Criteria:

- Melanoma stage III (regional lymph node recurrence). Will be selected the patients
with only one invaded lymph node confirmed by anatomopathological exam after lymph
nodes excision.

- Absence of visceral metastases verified by physical examination, chest radiography,
liver echography and brain-chest-liver CT-Scan.

- Age < 75 years, both genders

- ECOG 0-2, Karnofsky > 80%.

- Negative pregnancy test performed at the screening visit for fertile women.

- The potentially fertile women must use an oral contraception or an intra-uterine
device (IUD) until three months following the last injection of the study treatment.

- The patients must have fully recovered from surgery.

- HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24
or DGV HIV.

- HBV: The patients must be negative for the antigen, but can be positive for the
antibodies but with a negative DNA PCR.

- HCV: The patients must be negative for the antibodies.

- HTLV ½: The patients must be negative for the antibodies.

- Following laboratory results:

- Hemoglobin: ≥ 10 g/dl

- WBC: ≥ 4000/µl

- Lymphocytes: ≥ 700/µl

- Platelet count: ≥ 100.000/µl

- Serum creatinine: < 2.0 mg/dl or £ 177 mmol/l

- Serum Bilirubin: < 2.0 mg/dl or £ 34.2 mmol/l

- ASAT and ALAT: < 2.5 x the upper limit of normal.

Exclusion criteria:

- Patient with more than one invaded lymph node confirmed by anatomopathological exam.

- Presence of melanoma metastases discovered by clinical or radiological examination at
the screening visit.

- Patients must not have received any Chemotherapy, immunotherapy or radiotherapy
within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C
therapies).

- Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not
controlled HTA).

- Any serious active medical illnesses, for example: Active systemic infections
requiring of antibiotics, coagulation disorders or any other condition which requires
concomitant medications not allowed during this study.

- Presence of the second active cancer other than surgically cured non-melanoma skin
cancer or cervical carcinoma in-situ.

- Any affection requiring a systemic corticotherapy or a treatment by Interferon A.

- Any active auto-immune disease including the insulin-dependent diabetes or a
immunodeficiency. The vitiligo is not an exclusion criteria.

- Thyroid dysfunction not responsive to therapy.

- Positive Serology for HIV, HVB, HVC or HTLV1/2.

- Woman pregnant or nursing or without an effective contraception.

- Incapacity to give written consent.